Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2020 filed with the SEC

September 16, 2020August 16, 2022 Alterity Therapeutics

XBRL 30 June 2020 filed with the SEC

2020

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Related Posts

Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial

February 16, 2023May 23, 2023

Journal of Huntington’s Disease Publishes Benefits of PBT2

July 17, 2013August 16, 2022

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

June 30, 2020August 16, 2022

Recent Posts

Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065